Shenfu injection plus vinorelbine for elderly patients with non-small cell lung cancer in promoting the quality of life: a randomized controlled clinical trial

详细信息    查看全文

• 作者：Yan Hu (1)
  Anji Hou (1)
  Hongwei Zhang (1)
  Wei Zhou (1)
  Xiaoyan Shen (1)
  Yanli Huang (1)
  Li Zhou (1)
  
• 关键词：non ; small cell lung cancer ; quality of life ; toxicity ; shenfu injection ; vinorelbine
• 刊名：The Chinese-German Journal of Clinical Oncology
• 出版年：2010
• 出版时间：January 2010
• 年：2010
• 卷：9
• 期：1
• 页码：22-25
• 全文大小：143KB
• 参考文献：1. Scagliotti G. Optimizing chemotherapy for patients with advanced nonsmall cell lung cancer. J Thorac Oncol, 2007, 2(Suppl 2): S86-1. CrossRef
  2. Devlin JG, Langer CJ. Salvage therapy with vinorelbine in advanced non-small-cell lung cancer: a retrospective review of the Fox Chase Cancer Center experience and a review of the literature. Clin Lung Cancer, 2007, 8: 319-26. CrossRef
  3. Sekine I, Nokihara H, Sumi M, / et al. Docetaxel consolidation therapy following cisplatin, vinorelbine, and concurrent thoracic radiotherapy in patients with unresectable stage III non-small cell lung cancer. J Thorac Oncol, 2006, 1: 810-15. CrossRef
  4. Luo ZG, Chang JH, Yu H, / et al. Analysis of chemotherapy with 5-Fu by continous intravenous infusion and cisplatin in head and neck advanced cancer. Chin Oncol (Chinese), 2007, 17: 716-18.
  5. Huang JC, Li Y, Hu P, / et al. Clinical study of traditional Chinese medical herbs on portal embolus of 40 hepetacellular carcinoma patients. Oncol Prog (Chinese), 2007, 5: 598-01.
  6. Hirsh V, Desjardins P, Needles BM, / et al. Oral versus intravenous administration of vinorelbine as a single agent for the first-line treatment of metastatic nonsmall cell lung carcinoma (NSCLC): A randomized phase II trial. Am J Clin Oncol, 2007, 30: 245-51. CrossRef
  7. Hosomi Y, Shibuya M. Non-cisplatin based chemotherapy in advanced non-small cell lung cancer. GanTo Kagaku Ryoho, 2007, 34:527-32.
  8. Long SQ, Deng H, Wu WY, / et al. Effect of Shenfu injection on bone marrow inhibition of non-small cell lung cancer. Guangdong Med J (Chinese), 2007, 28: 1339-341.
  9. Song Q, Li Y. Effect of Shenfu Injection as complementary therapy on the quality of life of acute leukamia. J Jining Med Coll (Chinese), 2007, 30: 125-26.
  10. Zhang WW, Chen Y, Qian YM. Clinical Study of Shenfu Injection’s effect to inhibit adverse effect and enhance response rate on adriamycin based chemotherapy regimen. Henan Tradit Chin Med (Chinese), 2007, 27: 70-1.
  11. Guo ZN, Yang YF, Wu Y. Effect of Shenfu Injectionon Hematological toxic reactions induced by vinorelbine plus cisplatin in the treatment of non-small cell lung cancer. Chin Pharm (Chinese), 2006, 17:1888-890.
  12. Wu WY, Wang B, Zhang HB, / et al. Shenfu injection on vinorelbine plus cisplatin for treating advanced non-small cell lung cancer in quality of lify. Chin Tradit Pat Med (Chinese), 2007, 29: 14-8.
  
• 作者单位：Yan Hu (1)
  Anji Hou (1)
  Hongwei Zhang (1)
  Wei Zhou (1)
  Xiaoyan Shen (1)
  Yanli Huang (1)
  Li Zhou (1)
  
  1. Department of Oncology, Shanghai Seventh People’s Hospital, Shanghai, 200137, China
  

文摘

Objective The present study aimed to investigate the efficacy of Shenfu injection plus vinorelbine on the promotion of the quality of life (QOL) in elderly non-small cell lung cancer (NSCLC) patients. Methods A randomized single blind trial method was used. Forty-six patients with stage IIIB-IV of NSCLC were randomly divided into experimental group and control group. In the experimental group, the patients were treated with 50 mL Shenfu injection from day 1 to 14, plus vinorelbine (NVB) 25 mg/m2 on day 1 and 8. In the control group, the patients were only treated with NVB 25 mg/m2 on day 1 and 8. After two cycle’s of treatment, QOL, efficacy and toxicity were observed. Results The QOL was enhanced in both experimental group and control group. However, the difference of KPS after treatment in the experimental group was markedly higher than in the control group (14 ± 10 vs. 8 ± 10, t = 2.116, P = 0.04), improvement rate of QOL was better than in the control group (76.2% vs. 45.0%, χ2 = 4.188, P = 0.041), treatment related toxicity in the experimental group was also markedly lower than in the control group (χ2 = 3.866, P = 0.049), but the difference of efficacy between the two groups was not significant (14.3% vs. 15.0%, χ2 = 0.161, P = 0.688). Conclusion Shenfu injection plus vinorelbine can enhance QOL in elderly NSCLC patients.